Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals Inc | Chief Commercial Officer | Stock Options (Right to buy) | 220K | $5.69M | $25.84 | Dec 5, 2022 | Direct |
Turning Point Therapeutics, Inc. | SVP & Chief Commercial Officer | Common Stock | 0 | $76.00 | Aug 17, 2022 | Direct | |
Turning Point Therapeutics, Inc. | SVP & Chief Commercial Officer | Stock Option (right to buy) | 0 | Aug 17, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SNDX | Syndax Pharmaceuticals Inc | Dec 5, 2022 | 1 | $5.6M | 4 | Dec 5, 2022 | Chief Commercial Officer |
SNDX | Syndax Pharmaceuticals Inc | Dec 5, 2022 | 0 | $0 | 3 | Dec 5, 2022 | Chief Commercial Officer |
TPTX | Turning Point Therapeutics, Inc. | Aug 17, 2022 | 2 | -$2.79M | 4 | Aug 17, 2022 | SVP & Chief Commercial Officer |
TPTX | Turning Point Therapeutics, Inc. | May 31, 2022 | 2 | $0 | 4 | Jun 1, 2022 | SVP & Chief Commercial Officer |
TPTX | Turning Point Therapeutics, Inc. | May 31, 2022 | 0 | $0 | 3 | Jun 1, 2022 | SVP & Chief Commercial Officer |